Pinnacle Family Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$810K Buy
676
+1
+0.1% +$1.02K 0.34% 53
2026
Q1
$620K Buy
+675
New +$684K 0.29% 59
2025
Q1
Sell
-646
Closed -$499K 117
2024
Q4
$499K Hold
646
0.24% 69
2024
Q3
$572K Buy
+646
New +$581K 0.3% 63
2023
Q3
Sell
-569
Closed -$267K 97
2023
Q2
$267K Buy
+569
New +$239K 0.14% 83
2023
Q1
Sell
-565
Closed -$207K 107
2022
Q4
$207K Buy
+565
New +$200K 0.15% 91
2021
Q4
Sell
-2,056
Closed -$475K 139
2021
Q3
$475K Buy
+2,056
New +$507K 0.21% 70
2021
Q1
Sell
-3,097
Closed -$523K 135
2020
Q4
$523K Buy
3,097
+1,126
+57% +$168K 0.32% 58
2020
Q3
$292K Sell
1,971
-1,312
-40% -$203K 0.2% 53
2020
Q2
$539K Buy
3,283
+1,329
+68% +$204K 0.47% 38
2020
Q1
$271K Sell
1,954
-346
-15% -$47.5K 0.33% 48
2019
Q4
$302K Buy
2,300
+11
+0.5% +$1.27K 0.27% 61
2019
Q3
$256K Buy
2,289
+11
+0.5% +$1.23K 0.23% 66
2019
Q2
$252K Buy
2,278
+11
+0.5% +$1.29K 0.21% 70
2019
Q1
$294K Sell
2,267
-3
-0.1% -$365 0.26% 59
2018
Q4
$263K Buy
2,270
+9
+0.4% +$1K 0.18% 53
2018
Q3
$243K Buy
+2,261
New +$226K 0.13% 60

Other funds holding LLY

Pinnacle Family Advisors's LLY Position: Q2 2026 in Review

Pinnacle Family Advisors increased its Eli Lilly (LLY) stake by 0.15% in Q2 2026, buying an estimated $1.02K and bringing the position to 676 shares worth $810K. The position accounts for 0.34% of the portfolio, ranked #53.

Pinnacle Family Advisors first reported a position in LLY in Q3 2018 and has held it in 17 quarters since. 4,601 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Pinnacle Family Advisors held 676 shares of Eli Lilly worth $810K as of Q2 2026.
  • Pinnacle Family Advisors bought 1 Eli Lilly share in Q2 2026, an estimated $1.02K.
  • Eli Lilly made up 0.34% of Pinnacle Family Advisors's portfolio in Q2 2026, its #53 holding.
  • Pinnacle Family Advisors first reported a position in Eli Lilly in Q3 2018 and has held it in 17 quarters since.
  • 4,601 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Pinnacle Family Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.